SG Austria

What SG Austria does

SG Austria, operating under the brand Austrianova, is a Singapore-based B2B biotechnology company specializing in cell encapsulation technology. Its core platforms are two proprietary micro-encapsulation technologies — Cell-in-a-Box®, which builds a porous capsule around living human and animal cells to enable immuno-protection, free diffusion of nutrients and waste, and storage/transport; and Bac-in-a-Box®, which applies the same encapsulation principle to probiotic bacteria and yeast for stomach-acid protection and ambient storage. The company monetizes these platforms through a mix of technology licensing and partnership arrangements, plus professional-service revenue streams including US-FDA compliant GMP cell banking (GMP4Cells), standardized allogenic stem cell manufacturing, and full-cycle cell line development (sourcing, plasmid design, clone generation, in vitro/in vivo assay testing). Its customer base is concentrated in biotechnology and pharmaceutical enterprises requiring cell-biology services, cell-encapsulation IP, and GMP-compliant manufacturing inputs for therapeutic development programs.

Austrianova's go-to-market is enterprise-focused: it pursues direct B2B engagement with biotech and pharmaceutical counterparties, supplemented by scientific publications and press release distribution to build credibility, and increasingly by formal joint ventures and co-development partnerships. Recent strategic activity underscores a deliberate shift from pure service provider toward asset-light therapeutic co-development — most visibly through the September 2025 establishment of Klothonova, a 50/50 joint venture with publicly traded Avaí Bio (OTCQB: AVAI) to develop cell-based anti-aging therapies targeting α-Klotho protein, and through a Cell-in-a-Box® partnership with Avant Technologies for beta cell replacement in type 1 and insulin-dependent type 2 diabetes. The company completed a preferred equity financing in 2025 led by Checkmate Capital Group, whose CEO joined the board in April 2026, and completed a GMP Master Cell Bank for the Klothonova program in May 2026. With 1-10 employees, ISO 9001:2015 certification, and a broad portfolio of registered trademarks and named therapeutic applications spanning antibodies, cytokines, exosomes, cancer, metabolic disease, probiotics, agriculture, bioremediation, and cosmetics, the company operates as a lean, IP-centric platform licensing and specialty services business.

Leadership is held by Brian Salmons (CEO & President), Walter Gunzburg (Co-Founder), Louise Bussieres (CFO), and John Dangerfield (COO). The legal entity, Austrianova Singapore Pte. Ltd., is a Singapore private limited company with no public listing; ownership beyond the Checkmate Capital Group preferred equity stake and the 50/50 Klothonova JV interest is not publicly disclosed.

Name

SG Austria

Legal name

Austrianova Singapore

Website

https://sgaustria.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

1–10 employees

Short description

SG Austria (Austrianova) is a Singapore-based B2B biotechnology company that licenses proprietary Cell-in-a-Box® and Bac-in-a-Box® micro-encapsulation technologies and provides US-FDA compliant GMP cell banking, allogenic stem cell manufacturing, and cell line development services to biotechnology and pharmaceutical clients.

Ownership category

akta.pro rank

Product category

Cell Encapsulation Biotechnology Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD)

akta.pro secondary industries

Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI), Engineered Microbial Therapeutics (synthetic biology, gene circuits) (HLAAAFAD), Probiotic/Direct-Fed Microbial (DFM) Premixes (AFADAGAG)

Keywords

• Cell encapsulation services
• GMP cell banking
• Stem cell manufacturing
• Biotechnology services
• Cell line development

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. GMP Cell Banking Services: B2B revenue from providing GMP-compliant cell banking and processing services for biotech and pharmaceutical companies requiring FDA-compliant cell banks.
2. Cell Encapsulation Technology Licensing: Technology licensing and partnership revenue from Cell-in-a-Box and Bac-in-a-Box encapsulation technologies used by partner companies.
3. Stem Cell Manufacturing Services: Standardised allogenic cell therapy manufacturing services for treating various diseases including Graft versus Host disease and cancers.
4. Cell Line Development Services: R&D services including cell sourcing, plasmid design, clone generation and characterization, and in vitro/in vivo assay testing.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

SG Austria (operating as Austrianova) is a Singapore-based biotechnology company that develops and applies proprietary cell encapsulation technologies—Cell-in-a-Box® for living human and animal cells and Bac-in-a-Box® for probiotic bacteria and yeast. It also delivers related B2B cell biology services including US-FDA compliant GMP cell banking (GMP4Cells), allogeneic stem cell manufacturing, and complete cell line development R&D services for biotech and pharmaceutical customers.

Product overview

Austrianova (SG Austria) is a biotechnology company offering a portfolio of cell encapsulation and manufacturing technologies. The core offerings consist of two proprietary platform technologies: Cell-in-a-Box® for micro-encapsulation of living human and animal cells providing immuno-protection and localization, and Bac-in-a-Box® for encapsulation of probiotic bacteria and yeast providing stomach acid protection and ambient storage. These platforms are supported by non-encapsulated services including GMP Cell Banking (GMP4Cells) for FDA-compliant cell banking, Stem Cell Manufacturing for allogenic cell therapy, and Cell Line Development for complete R&D services. The technologies serve diverse applications across antibody and cytokine production, metabolic diseases, cancer therapy, agriculture, probiotics, and bio-remediation.

Differentiator

Problem solved

Functional benefit

Brands

• Cell-in-a-Box®: Protective micro-encapsulation technology for living cells providing immuno-protection and localization in patients
• Bac-in-a-Box®
• GMP4Cells

Products and services

• Cell-in-a-Box® Proprietary protective micro-encapsulation technology that protects, isolates, stores, and transports living human and animal cells, providing immuno-protection and localization in patients. The porous capsule allows free diffusion of nutrients in, waste products out, and biological molecules synthesized by the cells to escape. Designed for biotech and pharmaceutical customers developing cell-based therapies.
• Bac-in-a-Box® Proprietary encapsulation technology for probiotic bacteria and yeast that provides stomach acid protection and ambient storage. The porous capsule protects bacteria and yeast while allowing nutrient diffusion, growth within capsules, and subsequent release. Targeted at human probiotics, farming, agriculture, aquaculture, cosmetics, and bio-remediation applications.
• GMP Cell Banking (GMP4Cells) Full GMP (Good Manufacturing Practice) service for living eukaryotic human and animal cells, including preparation of cell banks and processing of cell lines in a US-FDA compliant manner for adherent or non-adherent qualified cells. For biotech and pharmaceutical companies requiring FDA-compliant cell banks.
• Stem Cell Manufacturing Standardized allogeneic cell therapy manufacturing service that can be used for all patients without requiring use of the patient's own cells. Applicable for treating Graft versus Host disease, various types of cancer, and infectious diseases. Targeted at biotech and pharmaceutical companies developing off-the-shelf cell therapies.
• Cell Line Development Complete cell R&D service from sourcing cells and designing appropriate plasmids to generating and characterising clones, with testing of cell clones in various in vitro or in vivo assays through an extensive network of trusted partners. For biotech and pharmaceutical customers needing custom cell line development.

Named customers2 records

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core.

• Avaí BiocoreStrategic or Co-development Partner · 1 September 2025Joint venture Klothonova established in September 2025, equally owned by Avaí Bio and Austrianova's affiliate SG Austria Pte. Ltd. Focused on restoring declining α-Klotho levels associated with aging and age-related conditions through cell-based therapy. Avaí Bio is an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging.
• Avant TechnologiescoreStrategic or Co-development PartnerPartnership for Cell-in-a-Box microencapsulation technology. Avant Technologies is evaluating advanced cells for potential application in diabetes therapy, specifically beta cell replacement for type 1 and insulin-dependent type 2 diabetes patients. The technology offers immunosuppression-free protection for transplanted insulin-producing cells.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• BioGaia: Swedish probiotics company developing probiotic products with protective delivery technologies for gut health applications. Comparable as a focused probiotics player whose product strategy could leverage encapsulation technology similar to Bac-in-a-Box®.
• Vertex Pharmaceuticals: Major biotech developing VX-880 and VX-264 (encapsulated stem cell-derived islet) cell therapies for type 1 diabetes. Represents both an overlapping therapeutic indication (T1D cell therapy) and a competitive alternative encapsulation approach to SG Austria's beta cell replacement platform.
• Cellares: Emerging cell therapy manufacturing automation company offering integrated cell therapy GMP production platforms. Comparable as a technology-enabled cell therapy manufacturing services provider targeting the same biotech customer base as SG Austria's GMP4Cells service.

Broad incumbents

• Catalent: Global CDMO (now under Novo Holdings ownership) offering cell therapy and biologics manufacturing services including cell banking capabilities. Comparable as a broad incumbent competing for cell therapy and GMP manufacturing contracts.
• AGC Biologics: Global CDMO providing mammalian cell culture, microbial fermentation, and cell therapy manufacturing services. Comparable as a broad incumbent offering GMP-compliant biologics and cell therapy manufacturing that overlaps with SG Austria's GMP4Cells service offering.
• Lonza Group: Global CDMO leader offering cell and gene therapy manufacturing services including GMP cell banking. Comparable as a broad incumbent providing GMP-compliant cell therapy manufacturing infrastructure that competes for similar biotech and pharma customers.
• Novonesis (formerly Novozymes): Global biosolutions leader (formed via Novozymes-Chr. Hansen merger) with extensive microbial encapsulation capabilities for probiotics, agriculture, and industrial biotechnology. Comparable as a broad incumbent in microbial encapsulation technologies overlapping with SG Austria's Bac-in-a-Box® applications.

Direct peers

• Seraxis: Private biotech developing encapsulated stem cell-derived islet therapies for type 1 diabetes. Directly comparable technology and indication overlap with SG Austria's Cell-in-a-Box® diabetes applications through Avant Technologies.
• Living Cell Technologies: ASX-listed cell encapsulation company developing encapsulated porcine cell therapies for Parkinson's disease and diabetes. Directly comparable as a cell encapsulation platform company focused on therapeutic cell delivery and immuno-isolation.
• Betalin Therapeutics: Israeli biotech developing a microencapsulation platform (ESCellarate™) for pancreatic islet cell transplantation in diabetes. Comparable as a microencapsulation-based cell therapy company targeting insulin-dependent diabetes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/AustrianovaST
• Facebookfacebook.com/austrianova
• LinkedInlinkedin.com/company/austrianova

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SG Austria